Colchicine-Induced Hepatotoxicity

Abbott, Collette E.; Xu, Ruliang; Sigal, Samuel H.

doi:10.14309/crj.2017.120

Cited by 23 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This morphological report was compatible with steatohepatitis ( Figure 1 ). However, these results were not consistent with colchicine-induced liver injury, which occurs in cases of drug overdose, characterized by typical histopathological elements, i.e., anisonucleosis with enlarged nuclei, multiple nucleoli and frequent mitotic figures arrested in metaphase 23 , which were not present.…”

Section: Case Reportcontrasting

confidence: 65%

“… 38 Colchicine has a narrow therapeutic range, and hepatotoxicity as a possible consequence of long-term administration has been shown. 23 In fact, colchicine intoxication with daily doses higher than 5 mg might determine liver toxicity. 13 , 38 Of note, the usual doses used to prevent FMF attacks do not seem to bring about a significant increase in liver enzymes in most cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report

Massaro

Pompili

Sicignano

et al. 2020

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

A 44-year-old Jewish woman with familial Mediterranean fever (FMF) developed non-alcoholic steato-hepatitis during colchicine treatment (2,5 mg per day), confirmed by both elastographic study and liver biopsy. A combined therapy with the interleukin-1 (IL-1) blocking agent canakinumab (150 mg every 4 weeks) and colchicine (at a reduced dose of 1.5 mg per day) was started. Three months later transaminases became normal, and six months later there was a marked improvement of liver fibrosis on the elastographic study. Hepatic involvement in FMF occurs ranging from nonspecific increase in liver enzymes to cryptogenic cirrhosis. Liver is mostly involved in patients bearing the homozygous M694V MEFV mutation, as in our case. IL-1 blockade has the power to halt or mitigate liver involvement in FMF patients, though further experience is required to assess its therapeutic potential in the most severe patients with hepatic disease who are partially responsive to long-term colchicine.

show abstract

Section: Case Reportcontrasting

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report

Massaro

Pompili

Sicignano

et al. 2020

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

“…There is a controversy around hepatotoxicity after colchicine treatment. Experimental studies have shown that colchicine causes hepatotoxicity, including acute hepatic necrosis and steatosis in animals [9,27]. Guo X. et al reported that CYP3A inhibition was associated with colchicineinduced hepatotoxicity in animals [28].…”

Section: Discussionmentioning

confidence: 99%

“…A previous study has shown that colchicine is associated with a risk of hepatotoxicity in gout patients prescribed febuxostat [8], which has also been reported to induce acute liver injury [9]. However, there are few studies regarding hepatic safety of colchicine as a prophylactic therapy in gout patients treated with febuxostat.…”

Section: Introductionmentioning

confidence: 99%

Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study

Moon

2020

JCM

View full text Add to dashboard Cite

Colchicine has been effectively used to prevent acute flares in patients with gout, but drug-related adverse events have frequently occurred. We investigated whether colchicine therapy with febuxostat is associated with hepatotoxicity in gout patients. Gout patients treated with (n = 121) or without (n = 57) colchicine were enrolled upon initiating febuxostat as a urate-lowering treatment, and clinical and laboratory data at diagnosis were compared. Logistic regression analysis was performed to evaluate the risk factors related to hepatotoxicity. Median age of the with-colchicine and without-colchicine groups was 51.0 (37.0–62.0) and 56.0 (43.5–68.5) years, respectively. During the three months of febuxostat prescription, the prevalence of hepatotoxicity was 13/121 (10.9%) in the with-colchicine group and 4/57 (7.0%) in the without-colchicine group, without statistical significance. The rate of colchicine use was not different between the study subjects with or without hepatotoxicity (76.5% vs. 67.1%, p = 0.587). Pre-existing liver disease was significantly associated with increased risk of hepatotoxicity after febuxostat treatment (odds ratio, 4.083; 95% confidence interval, 1.326–12.577; p = 0.014). Colchicine may be safely used as a prophylactic agent for gout patients with febuxostat. However, upon initiating febuxostat, it is recommended to monitor the development of acute liver injury in gout patients with underlying liver disease.

show abstract

“…Colchicine is the treatment currently used to inhibit hepatocellular secretion of collagen and stop fibrotic tissue production. Its efficacy has not been yet confirmed due to its severe adverse effects [3, 4]. The lack of an effective therapy to prevent progression of liver damage has generated several lines of research including the search for compounds with hepatoprotective activity.…”

Section: Introductionmentioning

confidence: 99%

A Sargassum fluitans Borgesen Ethanol Extract Exhibits a Hepatoprotective Effect In Vivo in Acute and Chronic Liver Damage Models

Quintal-Novelo

Rangel-Méndez

Ortiz-Tello

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

One of the leading causes of death worldwide, cirrhosis, is a liver condition characterized by chronic necrosis, inflammation, and fibrosis. Hepatoprotective compounds, such as antioxidants, can prevent fibrosis. Macroalgae (seaweed) contain high amounts of antioxidant compounds and are plentiful; indeed, species such as Sargassum fluitans Borgesen (Phaeophyceae) carpet many beaches in the Caribbean Basin. An in vivo assay was done evaluating the possible hepatoprotective effect of a Sargassum fluitans ethanol extract. Two murine liver damage models were employed: acetaminophen (APAP) in Balb/c mice to induce acute damage; carbon tetrachloride (CCl4) in Wistar rats to induce chronic damage. Serum liver enzyme levels and relative liver weight were measured, and histopathological and immunohistochemical analyses of liver tissue sections were done. Both APAP and CCl4 significantly raised serum enzyme marker enzymes. Administration of 50 mg/kg S. Fluitans ethanol extract reduced this APAP- and CCl4-induced elevation to normal levels. This effect was corroborated by the extract's inhibition of inflammation and fibrosis in liver tissue observed in the histopathological analysis. The analyzed S. fluitans ethanol extract exhibited an in vivo hepatoprotective effect in acute and chronic liver injury models.

show abstract

Colchicine-Induced Hepatotoxicity

Cited by 23 publications

References 18 publications

Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report

Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report

Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study

A Sargassum fluitans Borgesen Ethanol Extract Exhibits a Hepatoprotective Effect In Vivo in Acute and Chronic Liver Damage Models

Contact Info

Product

Resources

About